Author

M. Travis Quigley

Observed names: M.T. Quigley, Michael Travis Quigley

Observed institutions: Beth Israel Deaconess Medical Center, Hackensack University Medical Center, Mayo Clinic, VA Boston Healthcare System, Massachusetts General Hospital, Dana-Farber Cancer Institute, Tennessee Oncology, Bluebird Bio (United States)

OpenAlex ID: A5015925681

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

2019 · Noopur Raje, Jesus Berdeja, et al. · New England Journal of Medicine · 1,728

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

2017 · Jesus G. Berdeja, Yi Lin, et al. · Blood · 85

First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.

2017 · Jesus G. Berdeja, Yi Lin, et al. · Journal of Clinical Oncology · 57

Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma

2016 · J.G. Berdeja, Y. Lin, et al. · European Journal of Cancer · 13

Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

2023 · Jesus G. Berdeja, David Dingli, et al. · Blood · 6

Works count: 5

Citation count: 1,889

H-index: 5

I10-index: 4